Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing.

ABSTRACT: Viral vectors represent a bottleneck in the manufacturing of cellular therapies. Electroporation has emerged as an approach for non-viral transfection of primary cells, but standard cuvette-based approaches suffer from low throughput, difficult optimization, and incompatibility with large-scale cell manufacturing. Here, we present a novel electroporation platform capable of rapid and reproducible electroporation that can efficiently transfect small volumes of cells for research and process optimization and scale to volumes required for applications in cellular therapy. We demonstrate delivery of plasmid DNA and mRNA to primary human T cells with high efficiency and viability, such as > 95% transfection efficiency for mRNA delivery with < 2% loss of cell viability compared to control cells.

SUBMITTER: VanderBurgh JA 

PROVIDER: S-EPMC10133335 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature